CL2011000806A1 - Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. - Google Patents

Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.

Info

Publication number
CL2011000806A1
CL2011000806A1 CL2011000806A CL2011000806A CL2011000806A1 CL 2011000806 A1 CL2011000806 A1 CL 2011000806A1 CL 2011000806 A CL2011000806 A CL 2011000806A CL 2011000806 A CL2011000806 A CL 2011000806A CL 2011000806 A1 CL2011000806 A1 CL 2011000806A1
Authority
CL
Chile
Prior art keywords
dabigatran etexilate
stroke
atrial fibrillation
prevention
patients suffering
Prior art date
Application number
CL2011000806A
Other languages
English (en)
Inventor
Paul A Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41463075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000806(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2011000806A1 publication Critical patent/CL2011000806A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de etexilato de dabigatran para la prevención del ictus en pacientes que padecen fibrilación auricular, en el que el paciente no tiene factores de riesgo para acontecimientos hemorrágicos mayores; y medicamento que comprende 150 mg de etexilato de dabigatran.
CL2011000806A 2008-11-11 2011-04-12 Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. CL2011000806A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11341308P 2008-11-11 2008-11-11
US23755909P 2009-08-27 2009-08-27

Publications (1)

Publication Number Publication Date
CL2011000806A1 true CL2011000806A1 (es) 2011-11-11

Family

ID=41463075

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000806A CL2011000806A1 (es) 2008-11-11 2011-04-12 Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.

Country Status (21)

Country Link
US (3) US20110269799A1 (es)
EP (1) EP2355823A1 (es)
JP (1) JP2013510073A (es)
KR (1) KR20110082564A (es)
CN (2) CN103463083A (es)
AR (1) AR074107A1 (es)
AU (1) AU2009315730A1 (es)
BR (1) BRPI0921354A2 (es)
CA (1) CA2738884A1 (es)
CL (1) CL2011000806A1 (es)
CO (1) CO6382133A2 (es)
EA (1) EA201100755A1 (es)
EC (1) ECSP11011029A (es)
IL (1) IL211853A0 (es)
MA (1) MA32785B1 (es)
MX (1) MX2011004796A (es)
NZ (1) NZ592615A (es)
PE (1) PE20110432A1 (es)
TN (1) TN2011000227A1 (es)
TW (1) TW201031651A (es)
WO (1) WO2010055022A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358368A1 (en) 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
DK2550966T3 (en) 2011-07-25 2017-02-06 Dritte Patentportfolio Beteili Dabigatran amidoxic acid esters as prodrugs and their use as a drug
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
CN108254216B (zh) * 2018-03-15 2021-04-27 攀钢集团西昌钢钒有限公司 一种高炉槽的矿料取样方法、装置及可读存储介质
WO2020180489A1 (en) * 2019-03-06 2020-09-10 University Of Rochester Anticoagulant compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
JP2009543842A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応

Also Published As

Publication number Publication date
AR074107A1 (es) 2010-12-22
US20100322870A1 (en) 2010-12-23
CA2738884A1 (en) 2010-05-20
CN103463083A (zh) 2013-12-25
PE20110432A1 (es) 2011-07-16
MA32785B1 (fr) 2011-11-01
KR20110082564A (ko) 2011-07-19
NZ592615A (en) 2013-06-28
US20120277269A1 (en) 2012-11-01
WO2010055022A1 (en) 2010-05-20
CN102209546A (zh) 2011-10-05
ECSP11011029A (es) 2011-06-30
TN2011000227A1 (en) 2012-12-17
EP2355823A1 (en) 2011-08-17
MX2011004796A (es) 2011-05-30
BRPI0921354A2 (pt) 2019-09-24
TW201031651A (en) 2010-09-01
IL211853A0 (en) 2011-06-30
US20110269799A1 (en) 2011-11-03
EA201100755A1 (ru) 2011-12-30
AU2009315730A1 (en) 2010-05-20
JP2013510073A (ja) 2013-03-21
CO6382133A2 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CO6382133A2 (es) Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
CL2010001123A1 (es) Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07).
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
CO6311083A2 (es) 4-((1r,3s)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina para el tratamiento de la disfunción cognitiva
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
BR112015012497A2 (pt) combinações farmacêuticas
UY31790A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona
ES2325291A1 (es) "uso de un extracto de silybum marianum"